HIGHLIGHTS
- who: Chao Zhen from the Johns Hopkins University, United States have published the paper: Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis, in the Journal: (JOURNAL)
- what: Considering the large outcome differences in outcomes reported in previous studies, the authors aimed to resolve the limitations of individual trials and systematically assess the efficacy and safety of RTX in patients with IIM in this meta-analysis. Based on the European League Against Rheumatism (EULAR) recommendations for the management of SLE, RTX may be considered to treat . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.